Previous close | 0.1500 |
Open | 0.1500 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 22.50 |
Expiry date | 2024-05-17 |
Day's range | 0.1500 - 0.1500 |
Contract range | N/A |
Volume | |
Open interest | 109 |
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Insights into Nkarta's Financial Health and Strategic Developments in Cell Therapy
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investmentsStrong balance sheet, bolstered by recent $240.1 million offering, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural kil